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ABSTRACT16
This work presents a simulation study evaluating relative biological effectiveness at 10% survival
fraction (RBE10) of several different positron-emitting radionuclides in heavy ion treatment systems, and
comparing these to the RBE10s of their non-radioactive counterparts. RBE10 is evaluated as a function of
depth for three positron-emitting radioactive ion beams (10C, 11C and 15O) and two stable ion beams (12C
and 16O) using the modified microdosimetric kinetic model (MKM) in a heterogeneous skull phantom
subject to a rectangular 50 mm×50 mm×60 mm spread out Bragg peak. We demonstrate that the RBE10
of the positron-emitting radioactive beams is almost identical to the corresponding stable isotopes. The
potential improvement in PET quality assurance image quality which is obtained when using radioactive
beams is evaluated by comparing the signal to background ratios of positron annihilations at different
intra- and post-irradiation time points. Finally, the incidental dose to the patient resulting from the use of
radioactive beams is also quantified and shown to be negligible.
17
1 Introduction18
Heavy ion therapy (HIT) is a relatively new cancer treatment modality, with several facilities operating or19
under construction around the world1–3. A monoenergetic heavy ion beam deposits most of its energy20
within a narrow depth range - known as the Bragg Peak - with the peak dose depth determined by the21
beam energy, ion species and target composition4, 5. Irradiation of the entire target volume is achieved22
using a range of particle energies, either via a passive scatterer or a raster-scanned spot beam with varying23
energy. Due to the narrow depth range of the Bragg peak, together with minimal lateral scattering and the24
high relative biological effectiveness (RBE) of heavy ions, HIT delivers a highly conformal therapeutic25
dose to the target volume with a much lower entrance dose than is possible with photon therapy. HIT26
achieves a lower entrance dose compared to proton therapy, although unlike proton therapy, some dose is27
delivered beyond the distal edge of the target volume due to the fragmentation tail.28
The precision of HIT makes it particularly useful for treating deeply-situated tumours while minimising29
damage to adjacent healthy tissue4, 6–8. However, due to the large dose gradients, deviations between30
the treatment plan and the delivered dose distribution can result in significant adverse effects on healthy31
tissue, particularly if the treatment region is in the proximity of an organ at risk (OAR). Accurate real-time32
measurement of spatial dose distribution during irradiation will provide a mechanism for closed-loop33
control over the treatment process, minimising errors between the treatment plan and the actual delivered34
dose.35
During HIT, a fraction of the ions in the beam will undergo nuclear inelastic collisions. Fragmentation36
of nuclei either from the primary beam or in the target and entrance path result in the production of a37
range of stable and radioactive nuclei6. Some of these fragments are positron-emitting radionuclides,38
which continue to travel a short distance in the target before coming to a stop, where they eventually decay.39
Measuring of the distribution of these secondary positron-emitting fragments offers a unique opportunity40
for noninvasive, real-time and/or offline quality assurance (QA) in heavy ion therapy via positron emission41
tomography (PET)9–16.42
A large number of annihilation photons must be detected in order to obtain a PET image of sufficient43
quality for useful treatment QA. The cross-sections for inelastic ion collisions depend on several parameters,44
including incident ion species and energy, and the density and composition of the target17. These factors45
determine the mix of fragments produced, which, in turn, determines the number and distribution of46
positron-emitting radionuclides resulting from each beam spill. To improve image quality, several authors47
have proposed the use of positron-emitting radioactive nuclei (such as 11C, 15O or 10C) as the primary48
particle in the heavy ion beam. Most primary particles will survive intact to decay via positron emission at49
their stopping point, corresponding to the location of the Bragg peak. Therefore, for radioactive beams,50
the spatial distribution of the stopping points of primary particles is the dominant component of the PET51
image, while positron-emitting target and beam fragments making up a secondary component.52
Beamlines capable of producing beams of radioactive ion species such as 11C, 10C and 15O with53
sufficient dose rates and beam purity for therapeutic use are currently under development at the National54
Institutes for Quantum and Radiological Science and Technology (NIRS, QST) in Japan and other facilities55
around the world18–23.56
In order to perform proper treatment planning with positron-emitting radioactive beams, and to57
understand how their use will impact image-based QA, it is necessary to address three key research58
questions:59
1. How does the relative biological effectiveness (RBE) of polyenergetic radioactive beams vary as a60
function of depth within a spread out Bragg peak, and how does this compare to the corresponding61
stable ion species?62
2. What quantitative differences are expected between the maps of positron annihilation resulting from63
treatment with stable and positron-emitting radioactive ion beams, and how will these impact the64
use of PET images as an intra-treatment or post-treatment QA mechanism? and finally,65
3. What additional dose will be received by the patient if a positron-emitting radioactive beam is used66
instead of a stable beam?67
In this work, simulations of a simple treatment plan (consisting of a flat biological dose in a rectangular-68
prismatic primary treatment volume inside a human skull phantom) are performed for five primary nuclei69
(three positron-emitting and two stable) using the Geant4 Monte Carlo toolkit. The values of RBE10 (RBE70
at 10% survival fraction) are estimated across a range of depths along the beam path (in the entrance,71
SOBP and tail regions) using Kase’s modified microdosimetric kinetic model (MKM)24–26. The validity of72
using Monte Carlo simulations to evaluate RBE using the MKM has previously been established by Bolst73
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et al.27, 28; however, to our knowledge, this is the first time that this approach has been applied to estimate74
the RBE10 of a polyenergetic radioactive beam. The method can easily be extended to other homogeneous75
or heterogeneous targets and heavy ion species, and is a convenient and cost-effective alternative to in76
vitro experiments.77
Monte Carlo simulation-based 2D maps of positron yield obtained in a skull phantom using a spread out78
Bragg peak (with the same flat biological dose (in Gy(RBE)) delivered throughout the planned treatment79
volume) are compared across all beam types. The distribution of positron production in the target volumes,80
as measured during the beam-off periods during irradiation of the phantom with the radioactive and81
corresponding stable heavy ion beams were measured, and the resulting signal to background ratios82
(SBRs) estimated. The chosen physics models in the simulation are validated via experimental work83
conducted at NIRS’s HIMAC facility.84
Finally, the additional dose to the patient resulting from the use of radioactive beams is estimated to85
determine whether it poses any significant risk to the patient compared to the use of a stable ion beam.86
The remainder of this paper is organised as follows. A summary of key related work, including a87
description of the modified MKM which is adopted in this paper, is presented in Section 2. Details88
of the Monte Carlo simulations, including the phantom, physical and biophysical models used and the89
experimental validation of the selected physics models, the implementation of a pseudo-clinical beamline90
and treatment plan for stable and their corresponding radiactive ion beams are discussed in Section 3.91
Simulation results and analysis of the RBE10 values of stable and radioactive beams, the resulting positron92
yield maps and the incidental dose resulting from the use of the radiactive beams are presented and93
discussed in Section 4. Conclusions and proposed future work are presented in Section 5.94
2 Related Work95
The use of positron-emitting radioisotopes for heavy ion therapy has been investigated by a number of96
authors. In 2001, Urakabe et al. demonstrated that a positron-emitting 11C scanned spot beam could be97
directly used as the therapeutic agent29. However, the estimate of RBE10 used to obtain a flat biological98
dose was based on an extrapolation of previously-reported results for 12C in water, which was assumed99
to extend to human tissue30. Iseki et al. at NIRS used low-intensity monoenergetic 10C probe beams100
with between 104 and 105 particles per spill to estimate the depth of the therapeutic 12C beam’s Bragg101
peak, while keeping the dose received during the range measurement under 100 mGyE (a few percent of102
therapeutic dose)31. RBE of the radioactive beam was estimated via simulation using the one-dimensional103
HIBRAC beam transportation code from Sihver et al. combined with Kanai’s RBE model30, 32, 33. However,104
this work only considered monoenergetic 11C ion beams, and ignored the effects of low-LET fragmentation105
products, which resulted in an overestimation of the RBE for 11C. Augusto et al. used the FLUKA Monte106
Carlo toolkit to investigate the use of 11C beams either alone or in conjunction with 12C34. It was found107
that for beams with equivalent energy per nucleon incident on the same water phantom, 11C and 12C108
beams produce very similar fragmentation products, with the main differences being the relative yield of109
helium ions and several boron isotopes. While this study demonstrated the potential of using 11C in heavy110
ion therapy, it only considered monoenergetic beams of 11C at a fixed depth (100 mm) in a homogeneous111
water phantom. The composition of the phantom, the isotope and the specific beam energy are important112
factors affecting the fragmentation processs and the spatial distribution of positron-emitting nuclei which113
results35, 36.114
These works demonstrate the potential for using positron-emitting beams both for radiotherapy and115
for range verification. However, in order to conclusively establish their clinical utility, it is necessary to116
quantify their RBE and evaluate the quality of the resulting PET image in a clinically relevant configuration,117
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through the use of heterogenous tissue-equivalent phantoms and polyenergetic ion beams.118
Relative biological effectiveness (RBE) is an empirically-derived ratio which can be used to predict119
the physical dose of a specific type of radiation which will result in the same cellular survival fraction as a120
reference dose (typically a 200 keV X-ray beam)37, 38. The complex dependencies of RBE on the energy121
and type of radiation, as well the location of the target and the specific tissue types present, require the122
use of biophysical methods for accurate theoretical estimation of RBE39–41. The Microdosimetric Kinetic123
Model (MKM), proposed by Hawkins et al., is a widely-used method for estimating RBE in which the124
microdosimetric spectrum ( f (y)) is measured through the use of a tissue-equivalent proportional counter125
(TEPC)24. It was subsequently extended by Kase et al. to relate the saturation-corrected dose-mean lineal126
energy (ȳ∗) to the radiation sensitivity coefficient α of the linear quadratic model (LQM, measured in units127
of Gy−1 and Gy−2), such that the method can be applied to therapeutic heavy ion beams25, 26, 42. This128
modified MKM has been extensively validated for carbon ion therapy, and also extended to proton and129
helium ion therapy25, 26, 42–44.130
The RBE10 for an ion beam, defined as the ratio of the physical dose from a 200 kVp X-ray beam131
required to achieve a cellular survival fraction of 10% (D(10,R)) to the ion beam dose resulting in the same132



















For human salivary gland (HSG) tumour cells, the dose resulting in a survival fraction of 10%, D(10,R)134
is 5 Gy for 200 kVp X-rays; the LQM radiation sensitivity coefficient values are α0 = 0.13 Gy−1 and135
β0 = 0.05 Gy−2. ρ and rd are the density and the radius of the sub-cellular domain, and assumed to be136
0.42 µm and 1 g/cm3, respectively25.137
In this work, RBE10 is estimated using an extension to the modified MKM proposed by Bolst et138
al., whereby the mean path length < lpath > of the charged particles that cross the sensitive volume139
is introduced to account for the directionality of the radiation field when deriving the microdosimetric140
spectra f (y) in a non-spherical sensitive volume, as opposed to the average chord length used in isotropic141
fields27, 28.142
Although estimates of the RBE10 for radioactive beams have been reported previously, these have143
been calculated using simplified analytic models with parameters interpolated/extrapolated from limited144
experimental data from beams of stable isotopes in homogeneous targets45, 46. The assumption that145
the RBE of radioactive ion species can be estimated from its stable analog has not been previously146
demonstrated in the literature.147
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Interaction Energy Range Geant4 Model/Package
Radioactive Decay All energies G4RadioactiveDecayPhysics
Particle Decay All energies G4Decay
Hadron Elastic All energies G4HadronElasticPhysicsHP
Ion Inelastic 0–110 MeV Binary Light Ion Cascade
> 100 MeV QMDModel
Neutron Capture 0–20 MeV NeutronHPCapture
Neutron Inelastic 0–20 MeV NeutronHPInelastic
>20 MeV Binary Cascade
Proton Inelastic 0–9.9 GeV Binary Cascade
EM Interactions All energies G4EmStandardPhysics option3
Table 1. Hadron physics models used in all simulations
3 Method148
All Monte Carlo simulations were performed using the Geant4 toolkit (version 10.2.p03)47, 48. The149
hadronic physics models used in the simulations are listed in Table 1, while electromagnetic interactions150
were modelled using the standard Geant4 option 3 physics constructor (G4EmStandardPhysics option3).151
The hadronic physics processes and models are listed in Table 1.152
Section 3.1 details the methods used to experimentally validate the Geant4 simulation. The phantoms153
used in the simulations are described in detail in Section 3.2. In Sections 3.3, 3.4 and 3.5, the implementa-154
tion of the modified MKM for the evaluation of the RBE10 of pseudo-clinical, polyenergetic carbon and155
oxygen beams and their corresponding radioactive beams is described. Lastly, Section 3.6 describes a156
simulation study which examines the yield of different positron-emitting radionuclides during and after157
the irradiation of a skull phantom with radioactive and corresponding stable beams and introduces the158
metric used for the evaluation of the quality of the resulting annihilation maps.159
3.1 Experimental Validation of the Physics Models160
To validate the Monte Carlo physics models, several simulations evaluating depth-dose profiles and161
positron-emitting radionuclide yield were performed and compared with measurements obtained from162
equivalent physical experiments.163
All experiments were performed at the Heavy Ion Medical Accelerator in Chiba (HIMAC), Japan, with164
the stable ion beams produced at the primary beam course, and the radioactive ion beams at the secondary165
beam course19, 23. The peak energies of the non-radioactive 12C and 16O ion beams, as measured at the166
beamline nozzle, were 290 MeV/u and 400 MeV/u, respectively with an energy spread of σ = 0.2%. The167
peak energies of the radioactive 11C and 15O ion beams were 330 MeV/u and 290 MeV/u, respectively,168
each with an energy spread of σ = 5%. The nominal transverse diameter of all beams was 2 mm full169
width at half maximum (FWHM).170
3.1.1 Depth-Dose Relationship171
The experimental configuration shown in Figure 1 was used to compare the experimental and simulation-172










Figure 1. The experimental configuration used to estimate the depth-dose profile of the stable ion beams
in water, at the primary beam course (HIMAC, Japan); the radioactive beams were produced at the
secondary beam course (not shown in this image).
chamber (IC) with a sensitive volume of 36 mm3, inside a 300×300×300 mm3 water phantom23. The IC174
was encased within a 0.5 mm PMMA casing and moved along the path of the beam using a motorised175
stage, with an accuracy of 10 µm. The energy deposited within the ionisation chamber at each point along176
the beam was normalised to the energy deposited at the entrance (i.e. at the front of the phantom). All177
depth measurements were converted to water equivalent depth.178
For the simulation study, each beam was modelled using a monoenergetic incident beam with a179
Gaussian energy distribution, with the same peak energies and spreads as for the HIMAC beamlines. The180
simulated beams entered the water phantom perpendicular to its front surface (see Table 2), with an air181
gap of 2.5 m between the beamline nozzle and the phantom surface as per the corresponding experimental182
configuration. The energy deposited was scored in the water phantom using 1 mm3 voxels and summed183
over a 36 mm3 volume equivalent to the sensitive volume of the ionisation chamber used throughout184
the experimental measurements. Energy deposited in the sensitive volume (as a function of depth) was185
normalised to value observed at the entrance plateau.186
3.1.2 Positron-Emitting Fragmentation Product Yield187
The hadronic physics models of Geant4, including the Quantum Molecular Dynamics (QMD) ion hadronic188
inelastic scattering and Radioactive Decay physics models, were validated by comparing the simulated and189
experimentally estimated yields of 11C, 10C and 15O, the three dominant positron-emitting radionuclides190
generated during irradiation of a 100×100×300 mm3 PMMA phantom by monoenergetic 12C and 16O191
beams with energies of 290 MeV/u and 400 MeV/u, respectively.192
The experimental configuration is shown in Figure 2. The phantom was positioned such that the193









Figure 2. The experimental configuration used in HIMAC, Japan, to validate the QMD ion hadronic
inelastic scattering model used in the simulations. The phantom is positioned within the field of view
(FOV) such that the calculated location of the Bragg peak (indicated by a red dot) is placed at the centre of
the field of view (CFOV).
scanner14. 20 spills were used, with a beam intensity of 1.0×109 particles per second (pps). In each spill,195
the beam was on for 1.9 seconds and off for 1.4 seconds. List-mode PET data were collected intra-spill,196
and for 36 minutes after the final spill. Dynamic (4D) images were reconstructed using the 3D ordinary197
Poisson ordered-subset-expectation-maximisation algorithm (3D-OP-OSEM) with 1.5×1.5×1.5 mm3198
voxels. Temporal frame lengths were chosen so as to be able to observe decay over several half-lives of199
11C, 10C and 15O. Yields of each positron-emitting radionuclide were estimated by fitting the parameters200
of a simple analytical model to the observed time-activity curves (TACs). Total activity as a function of201
time t in a volume with initial activities of 11C, 10C and 15O of A0,C11, A0,C10 and A0,O15, respectively, is202
given by203
Atotal(t) = A0,C11e− ln(2)t/TC11 +A0,C10e− ln(2)t/TC10 +A0,O15e− ln(2)t/TO15 (4)
where TC11, TC10 and TO15 are the respective half-lives of 11C, 10C and 15O. Total activity is measured204
as a function of time across the build-up and Bragg peak region, defined as the region from the point at205
which the dose profile has risen 5% above the entrance plateau to the point after which the profile is below206
5% of the peak value.207
The individual initial activities for each radionuclide are then estimated for both the simulation results208
and the experimental data by fitting the model to the observed curve.209
For the simulation studies, monoenergetic 12C and 16O beams were directed perpendicularly to the210
surface of a simulated 10×10×30 cm3 PMMA with an air gap of 1.75 m between the beamline nozzle211
and the phantom surface, matching the experimental configuration. Density, mean excitation, ionisation212
potential and dimensions of simulated phantoms were chosen to match those used in the experiment.213
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Phantom Name Phantom material Dimensions
PMMA phantom PMMA 100×100×300 mm3
Water phantom Water 250×250×250 mm3
Skull phantom Bone 250×250×10 mm3
Brain Tissue (modelled as muscle) 250×250×240 mm3
Table 2. Phantom compositions
The spatio-temporal distributions of positron-emitting nuclei, positron production and annihilation were214
recorded with a scoring volume resolution of 1.5 mm, corresponding to the voxel dimensions in the215
experimental PET images. Simulated yield profiles were convolved with a Gaussian filter, with its FWHM216
equal to the estimated OpenPET spatial resolution (3.5 mm)14.217
3.2 Phantom Geometry218
The phantoms used in the simulation were rectangular prisms with compositions as listed in Table 2. All219
material compositions were based on data from the National Institute of Standards and Technology (NIST)220
database49.221
3.3 Estimation of RBE10 for a pseudo-clinical SOBP222
To evaluate and compare the RBE10 of polyenergetic stable and positron-emitting radioactive beams,223
sensitive 1 mm×1 mm×10 µm volumes were defined every 100 µm along the path of the beam. The lineal224
energy deposition spectrum in each volume for all interactions ( f (y)) was stored and used to calculate the225
RBE10 at that point, using (3) (equivalent results for monoenergetic carbon and oxygen ion beams with the226
energies listed in Supplementary Table S1 are presented in Supplementary Table S2). A correction factor227
1.05 were used to account for the difference in stopping power and density of water relative to brain tissue.228
A simple variance analysis method was used to estimate a sufficient number of primary particles to use229
in the simulations. M test simulations were conducted, each with N primary particles, with RBE estimated230
for each simulation and the mean and standard deviation (SD) calculated across the M simulations. The231
standard deviation should approach zero as N tends to infinity; therefore, in this experiment, N was232
progressively doubled with a fixed value of M = 50 until the ratio of standard deviation to mean was less233
than an arbitrary threshold of 1%. This analysis suggested that N = 107 would be sufficient to get a good234
estimate of RBE (95% probability of the estimated RBE being within ±2% of the true RBE).235
3.4 Carbon236
The spectrum for the simulated carbon beams was generated using an experimentally-validated model237
of the passively-scattered 12C beamline at HIMAC, which is known to produce a flat biological dose238
across a 60 mm depth range50. The spectra of the positron-emitting radioactive beams (10C and 11C) were239
based on the 12C spectrum from this beamline, by determining the energies for which the Bragg peaks of240
monoenergetic radioactive ion beams where located at the proximal and distal edges of the desired SOBP,241
and linearly mapping the weights of the energies of the 12C SOBP spectrum to this range of energies.242
Finally, the SOBPs were compared and confirmed to both correspond to the planned depths.243
3.5 Oxygen244
Currently a validated model of the 16O beamline does not exist. Therefore, generation of the 60 mm flat245
biological dose SOBP in the target depth range was achieved by performing monoenergetic Monte Carlo246
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simulations of an 16O beam at a range of energies (177, 237, 297, 345 and 418 MeV/u), and evaluating the247
RBE10 as a function of depth for each energy using the modified MKM (see Section 3.3 and Supplementary248
Table S2). This RBE was used to convert the physical dose deposited in the simulations to an estimated249
biological dose for the 5 evaluated energies. Profiles were then generated for other intermediate energies250
by interpolating between the simulated values in increments of 1 MeV/u. Finally, the target flat biological251
dose was achieved by adjusting the weights of each of these profiles such that a flat biological dose rate252
of 5 Gy(RBE)/min was achieved within the target depth range. The spectra of the positron-emitting253
radioactive beam (15O) was based on the 16O spectrum, with energies scaled such that the SOBP was254
positioned in the desired depth range (as per carbon).255
3.6 Positron-Emitting Radionuclide Yield Study256
The impact of using positron-emitting primary beams on interspill and post-irradiation image quality257
was evaluated by comparing the spatial distributions of positron decays observed in the simulation over258
several different intervals during treatment of the skull phantom. A simple treatment plan was designed259
for each primary particle type, aimed at producing a constant biological dose rate of ≈5 Gy(RBE)/min in260
a depth range of 78-138 mm within a skull phantom. A total of 1×109 primary particles were used in261
each simulation. As for the experimental validation study, twenty spills were simulated, with the beam on262
for 1.9 seconds and off for 1.4 seconds.263
The distributions of positron decays were acquired for each beam type between the first and second264
spill, during the first five inter-spill intervals, and in the five minutes following the final spill.265
The contrast-to-noise ratios (CNRs) between the inside and outside of the proximal, distal and upper266
lateral edges of the SOBP are computed for each image. The CNR provides a metric for objectively267







where µa and µb are the mean signal amplitudes and σa and σb are the standard deviations of the269
image intensity in two regions a and b of the image51, 52.270
3.7 Data Availability271
All data generated or analysed during this study are included in this published article (and its Supplementary272
Information files) or are available from the corresponding author on reasonable request.273
4 Results and Discussion274
4.1 Physics Model Validation275
Experimental and simulation-based depth-dose curves are shown in Figure 3; the difference between the276
locations of the Bragg peaks obtained from the simulated and the experimental 12C, 16O, 11C and 15O277
depth-dose profiles were 0.8 mm, 0.24 mm, 0.37 mm and 0.43 mm, respectively.278
The experimental and simulation yields of 10C, 11C, and 15O produced during the irradiation of a279
PMMA phantom using a 290 MeV/u 12C beam and a 400 MeV/u 16O beam are expressed as a percentage280
of the total positron-emitting radionuclide yield and are listed in Table 3.281
The close agreement between the experimental and simulated normalised depth-dose profiles and the282
relative yield estimations of the positron-emitting fragments demonstrate the validity of the simulation283
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Figure 3. Experimental and simulated energy deposited in the sensitive volume plotted as a function of
depth for the 12C, 16O, 11C and 15O ion beams. The deposited energy is normalised to value observed at
the entrance plateau.
Table 3. Relative yields of positron-emitting nuclei in experiment and simulation




12C 290 10C 5±3 4±2
15O 15±6 14±8
11C 44±10 43±10
16O 400 10C 7±7 7±5
15O 49±14 50±10
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Table 4. Means and standard deviations of the RBE10 for each beam evaluated at five depths (entrance,
start, middle and end of SOBP, and tail). At each depth, RBE10 is evaluated in 11 adjacent sensitive
volumes (every 100 µm along the path of the beam) and the mean and standard deviation calculated.
12C RBE10 11C RBE10 10C RBE10 16O RBE10 15O RBE10
Region Depth (mm) µ σ µ σ µ σ µ σ µ σ
Entrance 50 1.32 0.0577 1.31 0.0646 1.30 0.0511 1.51 0.0455 1.50 0.0469
Start of SOBP 81 1.61 0.184 1.61 0.182 1.56 0.148 1.84 0.137 1.84 0.173
Middle of SOBP 111 1.80 0.202 1.79 0.199 1.76 0.235 2.05 0.163 2.05 0.190
End of SOBP 131 2.21 0.251 2.23 0.258 2.20 0.256 2.59 0.215 2.46 0.187
Tail 171 1.15 0.396 1.12 0.317 1.12 0.365 1.28 0.501 1.27 0.407
model. The small differences between the experimental and simulated depth dose profiles for radioactive284
primary particles may be due to an underestimation of the initial energy spread, heterogeneity of the285
beryllium target leading to contamination with other fragments and systematic errors introduced by the286
ionisation chamber measurements.287
4.2 RBE and Biological Dose in Gy(RBE)288
Figure 4 presents a comparison of RBE10 as a function of depth for the positron-emitting radioactive289
beams and for the corresponding stable isotope beams (for clarity, RBE10 values are shown at depth290
increments of 3 mm; refer to Supplementary Spreadsheet 1 for a full list of RBE10 values evaluated at291
100 µm intervals for all ion species). In each case, the mean RBE10s of the stable and radioactive beams292
are well within each others’ 95% confidence interval. Radioactive-to-stable RBE10 ratios are also shown,293
with the mean values remaining very close to 1.0 in the entrance and SOBP. The larger confidence intervals294
in the tail region are due to very little energy being deposited beyond the end of the SOBP (as expected for295
heavy ion beams), resulting in significant statistical noise.296
Table 4 lists numerical values of the RBE10 obtained at the entrance, the beginning, middle and end of297
the SOBP, and tail region for each beam type. The mean and standard deviations presented are calculated298
over 11 consecutive 100 µm deep sample volumes along the beam path centred about the listed depth. In299
all cases, the mean RBE10s for the radioactive and corresponding stable ion beams are within one standard300
deviation of each other.301
The significance of this result is that it indicates that the evaluated radioactive ion beams are comparable302
to their non-radioactive counterparts in terms of relative biological effectiveness. Heavy ion therapy with303
any of the radioactive ion species examined in this study should be feasible, with only minimal changes to304
the current treatment planning algorithms required to account for the small differences in RBE10.305
4.3 Positron Yield306
Figure 5 shows the 2D annihilation maps obtained during and after the simulated delivery of 5 Gy(RBE)307
for each beam type to the target volume within the skull phantom. Images in the first column correspond308
to data acquired during the first beam-off interval (i.e. after one spill), the centre column show images309
following 5 spills, and finally, the last column shows images acquired during the five minutes (300 seconds)310
immediately after the completion of the 20th (and final) spill.311
The CNRs of the inside and outside of the proximal, distal and upper lateral boundaries of the SOBP312
images in Figure 5 are listed in Table 5.313
Positron annihilation maps acquired at different stages of the treatment process clearly demonstrate314
the potential improvements in range-verification QA that can be obtained with radioactive ion beams.315
Following a single spill, the boundaries of the SOBP are very clearly visible in the cases of 10C and 15O316
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Figure 4. Biological dose, physical dose and RBE10 for positron-emitting radioactive beams, together
with the ratio of radioactive-beam RBE10 to stable-beam RBE10, each shown as a function of depth within
the phantom. The objective is a uniform dose within a 60 mm SOBP, from 78 to 138 mm depth. For
carbon, 12C is shown in red, with 11C and the ratio of 11C:12C shown in green, and 10C and the ratio of
10C:12C shown in blue. 16O is shown in red, while both 15O and the ratio of 15O:16O is shown in green.
All confidence intervals are 95% (two standard deviations).
(Figure 5 (a) and (j)), due to their short half-lives (19.29 seconds and 122.24 seconds, respectively). The317
images from the 10C simulation also exhibit the the highest CNR values for all boundaries after both 1318
and 5 spills (i.e. the delivery of 5% and 25% of the total planned dose) and 5 minutes after the delivery319
of the full treatment for the distal boundary. 15O also exhibits an excellent CNR following a 5 minute320
acquisition, demonstrating the best results for proximal and distal edge. The two stable beams produce321
images which are indistinct in comparison to any of the radioactive beam images. Due to its half life of322
20.334 minutes, only a small number of positron annihilations resulting from decays of 11C are observed323
within the first beam-off period (Figure 5 (d)). The distal edge can be clearly seen, however the proximal324
edge is indistinct. Finally, in the long post-irradiation image acquisition (right column in Figure 5), most325
primaries from the 10C and 15O beams have decayed, resulting in very similar high-contrast images. A326
substantial number of primaries have now decayed in the case of 11C, resulting in the emergence of a327
well-defined edges to the SOBP; it is expected that a 11C beam with a post-irradiation image acquisition of328
20 minute or more will result in very high CNRs due to its longer half-life. By contrast, after a 5 minute329
acquisition, the distal and proximal edges of the SOBP remain indistinct in the case of 12C. 16O exhibits a330
more well-defined distal edge to its SOBP compared to 12C, however, the proximal edge is again poorly331
defined.332
The images also demonstrate one of the key differences between the radioactive and stable beams.333
For radioactive beams, positron annihilations principally occur in the vicinity of the stopping point of the334
primary particle. The intensity of the decay radiation observed in a PET image is therefore proportional to335
the number of primary particles which have arrived at that particular depth. The energy weightings required336
to achieve a flat biological dose have a bias towards higher energies (since more deeply-penetrating high-337
energy particles also deposit an entrance dose which is added to the dose deposited by lower energy338
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Figure 5. 2D positron annihilation maps resulting from 5 Gy(RBE) irradiation of the skull phantom,
during and after irradiation: after 1 of 20 beam spills (5% of the planned dose - first column), 5 of 20
beam spills (25% of the planned dose - centre column) and 5 minutes post full-treatment (right column);
Signal to background ratio (SBR) is quoted under each image.
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Table 5. Contrast-to-noise ratios (CNRs) corresponding to Figure 5; the highest CNR value in each
column is highlighted in bold.
Proximal Edge Lateral Edge Distal Edge
1 spill 5 spills 5 min 1 spill 5 spills 5 min 1 spill 5 spills 5 min
10C 156.47 332.99 122.36 120.26 286.72 190.95 125.38 338.18 335.90
11C 9.7344 19.567 57.338 17.731 39.356 108.26 15.415 39.075 202.55
12C 4.5779 8.2736 12.979 11.034 19.265 21.380 2.9674 4.6759 6.8661
15O 28.398 79.051 201.99 72.384 133.94 216.50 53.606 85.169 233.24
16O 3.7561 8.7385 15.572 14.183 23.685 26.484 5.6323 9.5223 14.268
beams). Therefore, the distal edge of the SOBP can be expected to be much brighter than the proximal339
edge, as is clearly evident in the images from the radioactive beams. By contrast, the contribution of340
primary or target fragmentation, which is relatively minor for the radioactive beams, is the only source of341
positrons in the case of the stable beams, and positron-emitting fragmentation products are produced to a342
varying extent along the entire length of the beam path (see Supplementary Tables S3 and S4). Therefore,343
the stable beams exhibit a flatter (although not completely flat) activity distribution in the SOBP, and344
weaker contrast between the SOBP and the entrance region.345
4.4 Radiation dose to patients346
Given the superiority of positron-emitting radioactive beams for intra- and post-treatment QA imaging, it347
is also important to consider whether or not the use of such beams would have any unintended side effects348
for the patient. From this perspective, the main difference for the patient is that an additional radiation dose349
will result from the use of a radioactive beam. The dose resulting from the decay of a positron-emitting350
radionuclide includes the kinetic energy of the positrons together with the 511 keV gamma photons351
resulting from their eventual annihilation; for a 11C beam, a 70 Gy(RBE) dose delivered to a 100 mm cubic352
treatment volume would require approximately 2.3×1011 particles, distributed throughout the treatment353
volume. This corresponds to an initial activity concentration of 1.3 MBq/cc, which is comparable to tissue354
concentrations of radiotracer which would be used in diagnostic 11C clinical PET imaging, and would355
deliver a biological dose‘ within the treatment volume of the order of 3-10 mSv. The additional dose356
rapidly falls off outside the treatment volume, and would be insignificant compared to the dose due to357
lateral scattering of particles.358
5 Conclusion359
This work aimed to quantitatively evaluate the therapeutic potential of positron-emitting radioactive heavy360
ion beams; in particular, with regard to the relative biological effectiveness of the beams compared to361
their non-radioactive counterparts, the spatial distribution of the positron-emitting annihilations generated362
during and after irradiation of the target, and the incidental dose to the patient. Monte Carlo simulations363
of heavy ion therapy using a pseudo-clinical spread out Bragg peak constructed with positron-emitting364
radioactive beams of 11C, 10C and 15O as well as stable 12C and 16O were undertaken with the Geant4365
toolkit.366
The simulation physics model was validated through a comparison of depth-dose curves for monoen-367
ergetic 11C, 12C, 15O and 16O beams and relative yield estimations of the positron-emitting fragments368
produced within the build-up and the Bragg peak region with experimental data for 12C and 16O obtained369
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from the HIMAC facility in Japan. The maximum difference between the location of maximum dose in370
the simulation and experimental data was 0.8 mm, while the maximum difference in mean relative yields371
of the secondary positron-emitting fragments was 2%.372
The radiobiological effectiveness (RBE10) of each beam was calculated for an SOBP extending from373
depths of 78 to 138 mm in a skull phantom using the modified microdosimetric kinetic model (MKM). The374
RBE10 of the radioactive ion beams was found to be within one standard deviation of the corresponding375
non-radioactive ion beams for all energies, indicating that the therapeutic efficacy of such beams should376
be very similar to beams of the corresponding non-radioactive ion.377
Finally, the additional dose to the patient resulting from the use of radioactive beams was estimated378
to determine whether it poses any unreasonable risk to the patient compared to the use of a stable ion379
beam. The additional dose was found to be comparable to that received during diagnostic clinical PET,380
and therefore negligible compared to the dose delivered to the target volume or surrounding tissues during381
the radiotherapy procedure.382
In summary, positron-emitting radioactive heavy ions are approximately equivalent to the correspond-383
ing stable isotope with respect to expected therapeutic properties in heavy ion radiotherapy, while being384
greatly superior to non-radioactive beams in terms of the potential for accurately imaging the treatment385
volume during and after treatment. The substantial increase in positron yield offered by positron-emitting386
radioactive beams for the same biological effective dose will allow the boundaries of the spread out Bragg387
peak in a PET image to be unambiguously identified, making the use of positron-emitting radioactive ions388
a compelling choice for heavy ion therapy.389
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